{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:10:05Z","timestamp":1750781405784,"version":"3.41.0"},"reference-count":0,"publisher":"Clujul Medical","issue":"2","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicine and Pharmacy Reports"],"abstract":"<jats:p>Background. Meningiomas are the most frequent tumors of the brain and spinal cord with a potency to recur in around one third of the cases and and invade surrounding tissue. Hypoxia driven factors like HIFs (Hypoxia inducible factors) are implicated in tumor cell growth and proliferation.\r\nAim. This study aims at determining the association of HIF 1 \u0251 with different histopathological grades and types of meningiomas.\r\nMethods. This prospective study was conducted on 35 patients. The patients presented with headache (65.71%), seizures (22.86%) and neurological deficits (11.43%). They underwent surgical excision and surgical tissue samples of these patients were histopathologically processed and microscopically graded and typed. Immunohistochemistry was performed using anti-HIF 1\u0251 monoclonal antibody. The nuclear expression of HIF 1 \u0251 was graded as &lt;10%: negative, 11-50%: mild to moderate positive, &gt;50%: strong positive.\r\nResults. Of the 35 cases so examined 20% were recurrent; 74.29% were WHO grade I with meningothelial type (22.86%), being the commonest; 57.14 % revealed mild to moderate positivity for HIF 1\u0251, while strong positivity was noted in 28.57%. Significant association was found between WHO grade and HIF 1\u0251 (p=0.0015) and between histopathological types and HIF 1\u0251 (p=0.0433). Furthermore, HIF 1\u0251 was also significantly associated with the recurrent cases (p=0.0172).\r\nConclusion. HIF 1\u0251 appears to be a marker and a promising target for effective therapeutics in meningiomas<\/jats:p>","DOI":"10.15386\/mpr-2059","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T11:36:02Z","timestamp":1681126562000},"page":"170-174","source":"Crossref","is-referenced-by-count":3,"title":["HIF 1 \u0251 \u2013 a promising target for the treatment of meningiomas"],"prefix":"10.15386","volume":"96","author":[{"given":"Shristi","family":"Butta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6100","published-online":{"date-parts":[[2023,4,10]]},"container-title":["Medicine and Pharmacy Reports"],"original-title":[],"link":[{"URL":"https:\/\/medpharmareports.com\/index.php\/mpr\/article\/download\/2059\/3043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medpharmareports.com\/index.php\/mpr\/article\/download\/2059\/3043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:35:29Z","timestamp":1750779329000},"score":1,"resource":{"primary":{"URL":"https:\/\/medpharmareports.com\/index.php\/mpr\/article\/view\/2059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,26]]}},"URL":"https:\/\/doi.org\/10.15386\/mpr-2059","relation":{},"ISSN":["2668-0572","2602-0807"],"issn-type":[{"type":"electronic","value":"2668-0572"},{"type":"print","value":"2602-0807"}],"subject":[],"published":{"date-parts":[[2023,4,10]]}}}